Acacia Pharma Group plc Correction: Notice Of Results
23 September 2021 - 09:10PM
UK Regulatory
TIDMACPH
Correction for date of KOL webcast
Acacia Pharma to Report its Interim Results for the Six Months
ended 30 June 2021 on 30 September 2021
Conference Call to be held on 30 September at 14.00 CEST/08.00
EST
Cambridge, UK and Indianapolis, US -- 23 September 2021, 13:00
CEST: Acacia Pharma Group plc ("Acacia Pharma" or the "Company")
(EURONEXT: ACPH), a commercial stage biopharmaceutical company
focused on developing and commercializing novel products to improve
the care of patients undergoing serious medical treatments such as
surgery, invasive procedures, or chemotherapy, announces that it
will report its interim results for the half year ended 30 June
2021 at 07.00 CEST on Thursday 30 September.
A presentation by Acacia Pharma's senior management team will be
webcast live the same day at 14.00 CEST (08.00 EST) and will
include an update on progress with the US commercialization of
Barhemsys(R) and Byfavo(R).
The webcast can be accessed from
https://www.globenewswire.com/Tracker?data=svn-mi2BzSSsfbIfaAOSAEusZSM5YOeTME2ary4dRG4CvFmGrpuhPMdSRXcU-gz-brk5guryoqu-xxvzodNQiJPjv_7MeVycQOIRBpQZCUI=
www.acaciapharma.com and a recording will be available after the
event.
The interim results report will be available at
https://www.globenewswire.com/Tracker?data=svn-mi2BzSSsfbIfaAOSAEusZSM5YOeTME2ary4dRG6Az5EIqJqKArv_ten_QRA9zVdpduazqcqq2O-KMbn6ezG_-KPGj7afARCgTxCRl1c=
www.acaciapharma.com in the Investors section from 07.00 CEST on 30
September and slides for the conference call will be made available
shortly before the start.
As previously announced, Acacia will also hold a KOL webinar
later the same day (30 September) at 18.00 CEST/12.00 EDT. Advanced
registration is required, and details can be found on our website
under the Media/Events section.
###
Contacts
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Mark Swallow, Frazer Hall, David
Gary Gemignani, CFO Dible
+44 1223 919760 / +1 317 505 1280 MEDiSTRAVA Consulting
mailto:IR@acaciapharma.com IR@acaciapharma.com +44 20 7638 9571
mailto:acaciapharma@medistrava.com
acaciapharma@medistrava.com
----------------------------------------------- ------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
----------------------------------------------- ------------------------------------
About Acacia Pharma
Acacia Pharma is a hospital pharmaceutical company focused on
the development and commercialization of new products aimed at
improving the care of patients undergoing significant treatments
such as surgery, other invasive procedures, or cancer chemotherapy.
The Company has identified important and commercially attractive
unmet needs in these areas that its product portfolio aims to
address.
Acacia Pharma's first product, Barhemsys(R) (amisulpride
injection) is marketed in the US for the management of
postoperative nausea & vomiting (PONV).
Byfavo(R) (remimazolam) for injection, a very rapid onset/offset
IV benzodiazepine sedative is approved and launched in the US for
use during invasive medical procedures in adults lasting 30 minutes
or less, such as colonoscopy and bronchoscopy. Byfavo is
in-licensed from Paion UK Limited for the US market.
APD403 (intravenous and oral amisulpride), a selective dopamine
antagonist for chemotherapy induced nausea & vomiting (CINV)
has successfully completed one proof-of-concept and one Phase 2
dose-ranging study in patients receiving highly emetogenic
chemotherapy.
Acacia Pharma has its US headquarters in Indianapolis, IN and
its R&D operations are centered in Cambridge, UK. The Company
is listed on the Euronext Brussels exchange under the ISIN code
GB00BYWF9Y76 and ticker symbol ACPH.
https://www.globenewswire.com/Tracker?data=svn-mi2BzSSsfbIfaAOSAEusZSM5YOeTME2ary4dRG5L1SR3mTgZ1kpwataEJML124_1Qn7jB5YmTXRfr8L22rInE8OksbzPjpShkveBzqs=
www.acaciapharma.com
(END) Dow Jones Newswires
September 23, 2021 07:10 ET (11:10 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2023 to Mar 2024